Navigation Links
World-first swine-flu vaccine trial reveals one dose provides 'strong immune response'
Date:9/3/2009

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

The pilot study, run by the University of Leicester and Leicester Hospitals, was trialled with 100 healthy volunteers, aged between 18 and 50.

Dr Iain Stephenson, who led the trial at the Leicester Royal Infirmary, said: "The clinical trial of Novartis MF59-adjuvanted cell-based A (H1N1) vaccine indicates that the "swine flu" vaccine elicits a strong immune response and is well-tolerated.

"Results showed that the serum antibody responses were highest among subjects who received two doses of vaccine, however a single vaccine dose also induced responses associated with protection against influenza.

"The findings showed that it is possible to induce protective antibody against A(H1N1) infection within two weeks of administration of a single low-dose adjuvanted vaccine."

Non-adjuvanted formulations were not evaluated in this part of the study and will be evaluated shortly

The trial evaluated the tolerability and immunogenicity of the vaccine, and tested different schedules of vaccination, in terms of time between vaccinations. The vaccine schedule was one or two doses of 7.5μg MF-59 adjuvanted surface-antigen A/California/2009 vaccine derived from cell-culture.

Dr. Stephenson, of the Department of Infection, Immunity and Inflammation at the University of Leicester is a clinical senior lecturer at the University, and a consultant in infectious diseases at the University Hospitals of Leicester NHS Trust. He said: "The aim of the trial was to find out how many doses and what type of vaccine is needed to give protection. These initial results should help to plan vaccination campaigns in the autumn, including doses and timings. We concluded that the MF59-adjuvanted A(H1N1) vaccine of low antigen content was well tolerated and generated antibody responses associated with protection against influenza, even after a single dose."

"The results suggest that one vaccine dose may be sufficient to protect against the A(H1N1) swine flu, rather than two. Larger trials are already underway around the world. Timings on when the vaccine will be available to governments will depend on the results of these clinical trials, and approvals by regulatory authorities''

The research found the vaccine is well tolerated with pain at the injection site the most frequent adverse event.

Additional pivotal trials with both cell culture and traditional egg based vaccines under way around the world that will include more than 6000 adults and children.

Previous research had indicated that two doses of the vaccine would be needed against swine flu. You can access earlier stories here:


'/>"/>

Contact: Ather Mirza
pressoffice@le.ac.uk
44-011-625-23335
University of Leicester
Source:Eurekalert

Related biology news :

1. Study of African traditional medicine will begin world-first clinical trial
2. World-first to predict premature births
3. A world-first in solar technology unveiled at Concordia University
4. Britains first swine-flu trials under way
5. Possible hepatitis C vaccine
6. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
7. New nanoparticle vaccine is more effective but less expensive
8. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
9. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
10. An Alzheimers vaccine?
11. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... 2017  Former NFL players who had repeated head injuries ... life, according to a preliminary study released today that will ... Meeting in Boston , April 22 to ... where the muscles and nerves work together, like walking, kicking ... ...
(Date:2/20/2017)... 20, 2017  Atrius Health and IBM (NYSE: ... agreement to develop a cloud based service designed ... holistic view of the multiple influences on an ... could be designed to support shared decision making ... innovative nonprofit healthcare organization with 875 physicians caring ...
(Date:2/18/2017)... , February 18, 2017 ... intrazellulären Zytokinen bei adoptiven Zelltherapie-Studien, Poster legt metaproteomische Analyse ... ... Inc. heute bekanntgab, wird Dr. Yoav Peretz , ... in der Entwicklung von Assays zum Nachweis intrazellulärer Zytokine ...
(Date:2/18/2017)... , ... February 17, 2017 , ... ... opened for business in Hong Kong. , Nerium International is proud to introduce ... Firming Body Contour Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury ...
Breaking Biology Technology: